{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"197"}],"title":"Experienced AE/SAE"}],"title":"Experienced AE/SAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"67"}],"title":"Experienced AE/SAE"}],"title":"Experienced SAE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"199"}],"units":"Participants"}],"description":"Adverse events, according to CTCAE v5.0.","groups":[{"description":"Atezolizumab 1200mg intravenously on day 1 every 3 weeks plus bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\\^2 intravenously on day 1 every 3 weeks","id":"OG000","title":"Atezolizumab Plus Bevacizumab Plus Chemotherapy"},{"description":"Bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\\^2 intravenously on day 1 every 3 weeks","id":"OG001","title":"Bevacizumab Plus Chemotherapy"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety population, patients who received at least 1 dose of treatment: 198 in ABC/200 in BC. But, one patient assigned in the BC arm received ABC. For the safety analysis, the patient is evaluated according to the treatment received irrespective of the allocated treatment at randomization (safety population: 199 in each arm).\n\nOf note, in the next section, all-cause mortality was assessed for all randomized, while serious adverse events/adverse events were assessed for the safety population.","reportingStatus":"POSTED","timeFrame":"From randomization to 90 days after the last dose of protocol treatment, up to 52 months.","title":"Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}